fb-pixel Skip to main content

Karuna’s experimental schizophrenia drug succeeds in advanced study

If approved by the FDA, the Boston biotech’s medicine would be the first new type of treatment for the disease in decades.

Pfizer buying Global Blood Therapeutics in $5.4 billion deal
Pfizer is buying sickle cell drug maker Global Blood Therapeutics in an approximately $5.4 billion deal as it looks to accelerate growth after its revenue soared during the pandemic.

Boston researchers want to create ‘off-the-shelf’ cell therapies to fight cancer
Boston Children’s Hospital and ElevateBio plan to spin out a company based on newly published research.

Alnylam says heart disease drug meets goal in clinical trial, stock rises
Alnylam Pharmaceuticals vaulted in premarket trading after Onpattro, the company’s drug for a nerve condition, met the main goal of a late-stage trial in patients with a form of heart disease.

Startup IDRx raises $122m to focus on combination drug treatments
A company founded by some big names in biotech is licensing small-molecule medicines from Merck KGaA and Blueprint Medicines.

Axcella’s experimental drug helps patients in small study of long COVID
The Cambridge biotech says participants reported improvements in their mental and physical condition.

More Life Sciences Headlines

Startup IDRx raises $122m to focus on combination drug treatments

A company founded by some big names in biotech is licensing small-molecule medicines from Merck KGaA and Blueprint Medicines.

Axcella’s experimental drug helps patients in small study of long COVID

The Cambridge biotech says participants reported improvements in their mental and physical condition.

PerkinElmer sells off three business units in $2.45 billion deal

The Massachusetts company is retaining its life sciences and diagnostics business, which will be renamed before the deal closes. PerkinElmer's stock rose 9 percent on Monday morning.

This billionaire has quietly driven Boston’s biotech industry for decades

He set in motion a series of events that created the company Moderna — and committed to being its first investor. But he still regularly rides his bike to work, and he “never viewed science as a way to make money."

‘Please do not erase’: A treasured whiteboard at Boston Children’s Hospital has not been touched for 15 years

Preserved for posterity on the 12th floor of a research building, the board captures notes from the former chief of surgery’s transformative cancer research.

FDA will consider Biogen’s ALS drug, despite mixed results in clinical trial

The Cambridge company’s experimental treatment targets a rare form of the deadly disease.

Key elements of influential Alzheimer’s study may have been fabricated, report says

The field of Alzheimer’s research has received a black eye with news that key elements of an influential study into the disease may have been fabricated.

Ginkgo Bioworks buys Zymergen for $300 million

The Boston company plans to integrate the California firm’s software into its cell programming technology.